Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications

Peter W. Andrews*, Uri Ben-David, Nissim Benvenisty, Peter Coffey, Kevin Eggan, Barbara B. Knowles, Andras Nagy, Martin Pera, Benjamin Reubinoff, Peter J. Rugg-Gunn, Glyn N. Stacey

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

84 Scopus citations

Abstract

Pluripotent stem cells may acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for evaluating the risks that they may pose for clinical use.

Original languageAmerican English
Pages (from-to)1-4
Number of pages4
JournalStem Cell Reports
Volume9
Issue number1
DOIs
StatePublished - 11 Jul 2017

Bibliographical note

Publisher Copyright:
© 2017

Fingerprint

Dive into the research topics of 'Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications'. Together they form a unique fingerprint.

Cite this